Effect of alendronate on proliferation of human osteoblast and the mRNA expression of osteoprotegerin and receptor activator of nuclear factor kappa B ligand / 中国组织工程研究

ABSTRACT

BACKGROUND:Alendronate is a new generation of diphosphate,which is the second generation of osteoporosis drugs.It is widely used to treat diseases related to increase of bone absorption in clinic.OBJECTIVE:To observe the effect of alendronate on the proliferation and the mRNA expression of osteoprotegerin(OPG) and receptor activator of nuclear factor kappa B ligand(RANKL) of human osteoblasts.DESIGN,TIME AND SETTING:A single sample observational experiment was performed at the Basic Research Institute of Chongqing Medical University from November 2007 to March 2008.MATERIALS:Osteoblasts were isolated from cancellous bone in a surgical operation.Alendronate was the product of Merck Sharp & Dohme S.p.A.METHODS:Osteoblasts were cultured with various concentrations of alendronate(1?10-9,1?10-8,1?10-7,1?10-6,1?10-5,1?10-4 mol/L).Osteoblasts cultured without alendronate were assigned as controls.MAIN OUTC0ME MEASURES:①The morphology and growth of osteoblasts were observed.②Effect of alendronate on the proliferation of osteoblasts were detected by MMT method.③The effect of various concentrations of alendronate on the mRNA expression of OPG and RANKL were detected by using RT-PCR.RESULTS:1?10-5 and 1?10-4 mol/L alendronate inhibited the proliferation of osteoblasts.1?10-9-1?10-6 mol/L alendronate promoted the proliferation of osteoblasts,and the 1?10-8 mol/L alendronate had the strongest effect.Alendronate inhibited RANKL mRNA expression in a concentration-dependent manner,1?10-5 mol/L alendronate had a strongest effect at 72 hours after culture(P